Savara News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.05.25	Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? (Benzinga)
23.12.24	Savara Announces New Employment Inducement Grant (Businesswire)
17.12.24	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Businesswire)
22.11.24	Savara Announces New Employment Inducement Grant (Businesswire)
13.11.24	Savara Announces Participation in Upcoming Healthcare Conferences (Businesswire)
12.11.24	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Businesswire)
04.11.24	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Businesswire)
22.10.24	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®” Airing on Lifetime® TV (Businesswire)
18.10.24	Savara Announces New Employment Inducement Grant (Businesswire)
01.10.24	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Businesswire)
27.09.24	Savara Announces New Employment Inducement Grant (Businesswire)
27.09.24	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Businesswire)
24.09.24	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Businesswire)
23.09.24	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Businesswire)
06.09.24	Savara Announces New Employment Inducement Grant (Businesswire)
03.09.24	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
16.08.24	Savara Announces New Employment Inducement Grant (Businesswire)
12.08.24	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Businesswire)
28.06.24	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Businesswire)
19.05.24	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Businesswire)
16.05.24	Savara Announces New Employment Inducement Grant (Businesswire)
09.05.24	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Businesswire)
07.05.24	Savara to Present at the Citizens JMP Life Sciences Conference (Businesswire)
08.04.24	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Businesswire)
22.03.24	Savara Announces New Employment Inducement Grant (Businesswire)
07.03.24	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Businesswire)
06.03.24	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Businesswire)
02.02.24	Savara Announces New Employment Inducement Grant (Businesswire)
31.01.24	Savara to Present at Two Upcoming Healthcare Conferences (Businesswire)
21.12.23	Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Businesswire)
20.12.23	Savara Added to the NASDAQ Biotechnology Index (Businesswire)
15.12.23	Savara Announces New Employment Inducement Grant (Businesswire)
21.11.23	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Businesswire)
09.11.23	Savara Reports Third Quarter Financial Results and Provides Business Update (Businesswire)
08.11.23	Savara to Present at the Jefferies London Healthcare Conference (Businesswire)
06.10.23	Savara Announces New Employment Inducement Grant (Businesswire)
05.09.23	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Businesswire)
10.08.23	Savara Reports Second Quarter Financial Results and Provides Business Update (Businesswire)
04.08.23	Savara Announces New Employment Inducement Grant (Businesswire)
13.07.23	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Businesswire)
26.06.23	Savara Added to Russell 3000® Index (Businesswire)
26.06.23	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Businesswire)
02.06.23	Savara to Present at the Jefferies Healthcare Conference (Businesswire)
15.05.23	Savara Reports First Quarter Financial Results and Provides Business Update (Businesswire)
05.05.23	Savara Announces New Employment Inducement Grant (Businesswire)
31.03.23	Savara Announces New Employment Inducement Grant (Businesswire)
30.03.23	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Businesswire)
06.03.23	Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference (Businesswire)
28.02.23	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
14.02.23	Savara Announces New Leadership Appointments (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	166.85	1.86 %	K V
ABB	55.94	1.56 %	K V
Holcim	67.60	1.11 %	K V
Sika	187.20	0.97 %	K V
Nestle	74.72	-0.92 %	K V
Lonza Grp	570.20	-1.25 %	K V
Alcon	63.20	-1.37 %	K V
Roche Hldg G	270.10	-1.50 %	K V
Novartis	102.32	-1.60 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Savara Aktie VALOR 36593404 / ISIN US8051111016

Nachrichten zu Savara Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten